Welcome to Mallinckrodt Institute of Radiology
The MIR Cyclotron Facility, which consists of four cyclotrons, provides radionuclides and standard and novel radiopharmaceuticals to the research and medical communities. Its staff is experienced in Food and Drug Administration Investigational New Drug (IND) submissions, both for new indications and first-in-human translation. Used for research and clinical practice, these agents meet or exceed user requirements, while safely and reliably ensuring the highest level of quality within federal regulations and guidelines. The Cyclotron Facility has an NRC commercial radiopharmacy distribution license, as well a license from the FDA to produce three ANDA drugs. The nuclear pharmacy is licensed by the State Board of Pharmacy.
The PET Radiotracer Translation and Resource Center (PET-RTRC) at Mallinckrodt Institute of Radiology develops and disseminates a broad portfolio of PET radiotracers used in preclinical and human imaging studies throughout the nation. The center, the first of its kind, is leading the way for a nationwide network of collaborators seeking to advance the mission of precision medicine. Funded by a P41 grant from the NIH’s National Institute of Biomedical Imaging and Bioengineering, the PET-RTRC Center continues a long legacy of PET innovation and collaboration at MIR.